11/10
05:18 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.
11/7
03:46 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.
11/7
11:09 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Barclays PLC from $72.00 to $88.00. They now have an "overweight" rating on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Barclays PLC from $72.00 to $88.00. They now have an "overweight" rating on the stock.
11/7
09:41 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citizens Jmp from $69.00 to $102.00. They now have a "market outperform" rating on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citizens Jmp from $69.00 to $102.00. They now have a "market outperform" rating on the stock.
11/4
05:38 pm
ptgx
Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting [Yahoo! Finance]
Low
Report
Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting [Yahoo! Finance]
10/28
10:58 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $88.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $88.00 price target on by analysts at Truist Financial Corporation.
10/28
09:14 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Wedbush from $70.00 to $86.00. They now have an "outperform" rating on the stock.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Wedbush from $70.00 to $86.00. They now have an "outperform" rating on the stock.
10/28
08:09 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $82.00 price target on the stock.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $82.00 price target on the stock.
10/17
07:20 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/13
10:12 am
ptgx
Why Johnson & Johnson Is Eyeing Protagonist Therapeutics: The Rationale [Seeking Alpha]
Low
Report
Why Johnson & Johnson Is Eyeing Protagonist Therapeutics: The Rationale [Seeking Alpha]
10/13
09:07 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
High
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
10/13
08:44 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $112.00 price target on by analysts at Johnson Rice.
High
Report
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $112.00 price target on by analysts at Johnson Rice.
10/13
06:57 am
ptgx
J&J in talks to acquire Protagonist Therapeutics [Yahoo! Finance]
Medium
Report
J&J in talks to acquire Protagonist Therapeutics [Yahoo! Finance]
10/12
03:05 am
ptgx
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today [Yahoo! Finance]
High
Report
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today [Yahoo! Finance]
10/8
08:09 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
10/7
06:02 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $74.00 price target on by analysts at Johnson Rice.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $74.00 price target on by analysts at Johnson Rice.
10/7
10:06 am
ptgx
Protagonist Therapeutics (PTGX): Evaluating Valuation After a 65% Year-to-Date Share Price Surge [Yahoo! Finance]
Medium
Report
Protagonist Therapeutics (PTGX): Evaluating Valuation After a 65% Year-to-Date Share Price Surge [Yahoo! Finance]
9/18
06:44 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
9/17
11:46 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
9/17
08:05 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $72.00 price target on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $72.00 price target on the stock.
9/15
11:15 am
ptgx
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 [Yahoo! Finance]
Low
Report
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 [Yahoo! Finance]
9/13
05:50 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
9/12
08:03 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $73.00 price target on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $73.00 price target on the stock.
9/11
08:06 pm
ptgx
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency [Yahoo! Finance]
Low
Report
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency [Yahoo! Finance]